Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by Garp1on Jul 26, 2015 8:23pm
129 Views
Post# 23961537

RE:RE:RE:Evaluating the company's performance in the US-1tem 1

RE:RE:RE:Evaluating the company's performance in the US-1tem 1Palinc, Luc is a bean counter and always has been. If he doesn't see the bean, they do not exist. Look at his history in Thera, hes been consistent and as not changed. Any dynamic CEO would set tangible, measurable and timely goals for the company and work towards meeting them. This is how you show growth potential and show value to investors. With that type of an approach during the Q2 presentation this would probably have yielded a very strong share price increase. Instead we get the view that things will happen when they happen, that we will try to achieve in an unknown time frame the same sales that we had before, that we will not invest in other areas until we get a nice little cushion of money and that things seem to be going along fine. The net result of that type of an approach is that you get valued as if you were a company that has matured and shows a normal growth pattern, hence a basic and low P/R. Now the money cushion has been bought at a very high price to give the comfort level that Luc likes as a bean counter. I hope he uses some of the money to develop is talent as a CEO instead of a CFO.
Bullboard Posts